NEVVI Medicare utilization intelligence
or

← back

Provider profile

GOPALAN, NANDA MD

Hematology-Oncology · NPI 1215975321 · EL PASO, TX

1
Groups
46
Codes · 2024
31,885
Disclosed services

GOPALAN, NANDA is a Hematology-Oncology in EL PASO, TX, a member of 1 medical group, who billed 46 distinct codes to Medicare Part B in 2024.

Groups: TEXAS ONCOLOGY PA (DALLAS, TX)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

31,885
disclosed services
46
codes billed to Medicare Part B
Prior year · CY2023 15,655 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1453 Injection, fosaprepitant, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9271 Injection, pembrolizumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
36415 Insertion of needle into vein for collection of blood sample
J2469 Injection, palonosetron hcl, 25 mcg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J0640 Injection, leucovorin calcium, per 50 mg
80053 Blood test, comprehensive group of blood chemicals
J1626 Injection, granisetron hydrochloride, 100 mcg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9190 Injection, fluorouracil, 500 mg
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
85055 Reticulated (young) platelet measurement
J1200 Injection, diphenhydramine hcl, up to 50 mg
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
96523 Irrigation of implanted venous access drug delivery device
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96411 Administration of additional new drug or substance into vein using push technique
82378 Carcinoembryonic antigen (cea) protein level
83615 Lactate dehydrogenase (enzyme) level
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J3490 Unclassified drugs
82607 Cyanocobalamin (vitamin b-12) level
82746 Folic acid level, serum
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99195 Drawing of blood for a medical problem
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
38222 Biopsy and aspiration of bone marrow sample for diagnosis
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.